Caption Management’s ClearPoint Neuro CLPT Stock Holding History

Caption Management’s Portfolio CLPT Stock Details CLPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-17,229	Closed	-$329K	–	1540
2021 Q2	$329K	Buy	+17,229	New	+$333K	﹤0.01%	1120

Other funds holding CLPT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

EIM

Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return

CM Management Gulf Breeze, Florida $120M AUM 37.12% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Caption Management's CLPT Position: Q3 2021 in Review

Caption Management sold out of ClearPoint Neuro (CLPT) in Q3 2021, closing a stake of 17,229 shares — an estimated $329K sold.

Caption Management first reported a position in CLPT in Q2 2021 and held it in 1 quarter. The position peaked at $329K in Q2 2021. 69 funds tracked by Wall St. Rank hold CLPT as of Q3 2021.

Caption Management reported no remaining ClearPoint Neuro position as of Q3 2021 after selling out during the quarter.
Caption Management sold 17,229 ClearPoint Neuro shares in Q3 2021, an estimated $329K.
Caption Management first reported a position in ClearPoint Neuro in Q2 2021 and held it in 1 quarter.
Caption Management's ClearPoint Neuro position peaked at $329K in Q2 2021.
69 funds tracked by Wall St. Rank held ClearPoint Neuro as of Q3 2021.

Based on Caption Management's 13F filing for Q3 2021, filed 12 Nov 2021.